Given the lack of a gold standard, the clinical usefulness of Comprehensive Genomic Profiling (CGP) has not been established. This systematic review aimed to evaluate evidence about the clinical benefit of CGP for patients with Non-small cell lung carcinoma (NSCLC). All controlled studies that evaluated the ability of CGP to detect actionable targets (ATs) reported increases in the number of samples with ATs. The frequency of ATs detected in uncontrolled case series ranged from 0.7 % for RET mutations to 45 % for EGFR mutations. The studies that evaluated therapies targeted to EGFR, ALK, ROS-1, MET, and RET mutations documented significant improvement in clinical outcomes. This review suggests that CGP tests may be clinically helpful for treating patients with NSCLC. Although current evidence is associated with a high risk of bias, the significant impact of NSCLC on individuals and society may justify the routine use of CGP testing for this disease.

由于缺乏金标准，综合基因组分析 (CGP) 的临床实用性尚未确立。本系统评价旨在评估 CGP 对非小细胞肺癌 (NSCLC) 患者的临床益处的证据。所有评估 CGP 检测可操作目标 (AT) 能力的对照研究都报告说，具有 AT 的样本数量有所增加。在不受控制的病例系列中检测到的 AT 频率范围从 RET 突变的 0.7% 到 EGFR 突变的 45%。评估针对 EGFR、ALK、ROS-1、MET 和 RET 突变的疗法的研究记录了临床结果的显着改善。本综述表明 CGP 检测可能对治疗 NSCLC 患者有临床帮助。尽管目前的证据与高偏倚风险相关，